306 related articles for article (PubMed ID: 24496329)
1. Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.
Marchesi I; Giordano A; Bagella L
Cell Cycle; 2014; 13(4):516-27. PubMed ID: 24496329
[TBL] [Abstract][Full Text] [Related]
2. PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis.
Zoroddu S; Marchesi I; Bagella L
Clin Epigenetics; 2021 Aug; 13(1):156. PubMed ID: 34372908
[TBL] [Abstract][Full Text] [Related]
3. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Marchesi I; Bagella L
World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
[TBL] [Abstract][Full Text] [Related]
4. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
5. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
6. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
7. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
8. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
[TBL] [Abstract][Full Text] [Related]
9. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
10. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
11. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
12. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
13. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
14. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
15. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
16. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
[TBL] [Abstract][Full Text] [Related]
17. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells.
Juan AH; Kumar RM; Marx JG; Young RA; Sartorelli V
Mol Cell; 2009 Oct; 36(1):61-74. PubMed ID: 19818710
[TBL] [Abstract][Full Text] [Related]
18. A new kinetochore component CENP-W interacts with the polycomb-group protein EZH2 to promote gene silencing.
Koh W; Park B; Lee S
Biochem Biophys Res Commun; 2015 Aug; 464(1):256-62. PubMed ID: 26111449
[TBL] [Abstract][Full Text] [Related]
19. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
20. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Zhang Q; Padi SK; Tindall DJ; Guo B
Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]